BC Partners has begun the sale of Greek drugmaker Pharmathen, one of two healthcare divestments worth more than $3.6bn that the buyout firm wants to complete this year, with the hiring of investment bank Jefferies, two sources said.
Pharmathen focuses on developing, manufacturing and out-licensing complex generic drugs and could be valued at about $1.8bn, the sources told Reuters, speaking on condition of anonymity.
BC Partners is a British international investment firm with over $40bn of assets under management across private equity, credit and real estate in Europe and North America.
BC Partners declined to comment. Jefferies was not immediately available for comment.
Source: Reuters
Can’t stop reading? Read more
Blackstone taps bond market as private credit BDCs end issuance drought
Blackstone taps bond market as private credit BDCs end issuance drought Blackstone's private...
EQT raises the stakes with revised $12.3bn bid for Intertek
EQT raises the stakes with revised $12.3bn bid for Intertek EQT has tabled an improved takeover...
Temasek’s Azalea bets on evergreen structure to democratise private equity access
Temasek's Azalea bets on evergreen structure to democratise private equity access Azalea, a unit...